University Hospital Cologne

Researchers

• RBReinhard Büttner

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas

  NCT07888647· Phase 2· German Cancer Research Center· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Nationwide Children's Hospital· Source

• Not yet recruiting

  Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care

  NCT07699640· Heinrich-Heine University, Duesseldorf· Source

• Not yet recruiting

  Stratification and Treatment in Early Psychosis Study -ASSIST

  NCT07326124· Phase 3· University of Oxford· Source

• Not yet recruiting

  A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

  NCT07850635· Phase 1· SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany· Source

• Not yet recruiting

  Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

  2024-517295-37-00· Phase 3· University Of Cologne· Source

• Not yet recruiting

  PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%

  NCT07877584· Phase 3· German Cancer Research Center· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· AbbVie· Source

• Recruiting

  A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors

  2024-518348-19-00· Phase 1· Novartis Pharma AG· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

  NCT07825064· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A study to test a new drug (TRP-001) given before prostate cancer surgery in patients with very high-risk Prostate cancer.”

  2026-526406-32-00· Phase 1· Torpedo Pharmaceuticals AG· Source

• Not yet recruiting

  Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial

  NCT07840456· Phase 2· University Hospital, Basel, Switzerland· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

  2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

  NCT07412704· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  Stratification and Treatment in Early Psychosis Study - ENHANCE

  NCT06778564· Phase 3· University of Oxford· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source

• Not yet recruiting

  Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair

  NCT07380932· Atrial Fibrillation Network· Source

• Recruiting

  A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  NCT07807163· Phase 2· Bicara Therapeutics· Source

• Not yet recruiting

  NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

  NCT07178730· Phase 3· Women's Cancer Study Group GmbH· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

  2025-524335-39-00· Phase 3· Gilead Sciences Inc.· Source

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  PULSed Field Ablation for Atrial Fibrillation Using a Balloon for Early Intervention - Study

  NCT07621003· Asklepios proresearch· Source

• Recruiting

  A trial to learn how safe elecoglipron is and how well it works in adults living with obesity or excess body weight with or without type 2 diabetes

  2025-524688-19-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

  2025-524336-19-00· Phase 3· Gilead Sciences Inc.· Source

• Not yet recruiting

  Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients

  NCT06414122· University of Cologne· Source

• Recruiting

  A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

  NCT07688213· Phase 2· Sanofi· Source

• Recruiting

  Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

  NCT07549698· Phase 1/2· CRISPR Therapeutics AG· Source

• Recruiting

  The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID?

  2025-524443-12-00· Phase 2· Goethe University Frankfurt· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

  NCT07672236· Phase 3· OncoZenge AB· Source

• Recruiting

  A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

  NCT07600476· Phase 1· Kupando GmbH· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· AbbVie· Source

• Not yet recruiting

  PHOENIX - ECP: Extracorporeal PHotopheresis for immune-related cOlitis and/or hEpatitis in advanced melaNoma with inadequate response to steroId eXposure

  2026-526261-14-00· Phase 2· Therakos Europe Limited· Source

• Not yet recruiting

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· Phase 3· University of Heidelberg Medical Center· Source

• Recruiting

  Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

  NCT07486817· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07192952· Phase 3· Bayer· Source

• Recruiting

  PREFer

  NCT06916416· Phase 2· University Of Cologne· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma

  2025-524014-29-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Pembro-FLASH

  NCT06045159· Phase 2· University Of Cologne· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

  NCT07285655· Phase 3· Liquidia Technologies, Inc.· Source

• Recruiting

  Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support

  NCT07655479· University Hospital of Cologne· Source

• Recruiting

  A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  NCT07226843· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

  2025-523079-44-00· Phase 3· Ascendis Pharma Endocrinology Division A/S· Source

Showing 50 of 329.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers31 recruiting
• Lung cancer29 recruiting
• Chronic lymphocytic leukaemia12 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• HIV9 recruiting
• Liver and biliary tract cancer9 recruiting
• Lupus (SLE)8 recruiting
• Multiple myeloma7 recruiting
• Parkinson disease7 recruiting
• Heart failure6 recruiting
• Alzheimer disease5 recruiting
• Diffuse large B-cell lymphoma5 recruiting
• Gastric and oesophageal cancer5 recruiting
• Hodgkin lymphoma5 recruiting
• Melanoma5 recruiting
• Ovarian cancer5 recruiting
• Acute myeloid leukaemia4 recruiting
• Atrial fibrillation4 recruiting
• Bladder cancer4 recruiting
• Dermatomyositis and polymyositis (myositis)4 recruiting
• Glioblastoma4 recruiting
• Head and neck cancer4 recruiting
• High blood pressure4 recruiting
• Mantle cell lymphoma4 recruiting
• Metastatic breast cancer4 recruiting
• Pancreatic cancer4 recruiting
• Polycystic kidney disease4 recruiting
• Prostate cancer4 recruiting
• Amyloidosis3 recruiting
• Coronary artery disease3 recruiting
• Dystonia3 recruiting
• Essential tremor3 recruiting
• Follicular lymphoma3 recruiting
• Neuroblastoma3 recruiting
• Rheumatoid arthritis3 recruiting
• Sarcoma3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Triple-negative breast cancer3 recruiting
• Aortic aneurysm2 recruiting
• Bronchiectasis2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Colorectal cancer2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Hepatitis B2 recruiting
• Immune thrombocytopenia (ITP)2 recruiting
• Macular degeneration2 recruiting
• Myelodysplastic syndromes2 recruiting
• Nephrotic syndrome2 recruiting
• Schizophrenia2 recruiting
• Sjögren's disease2 recruiting
• Stroke2 recruiting
• Type 2 diabetes2 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic stenosis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Brain aneurysm1 recruiting
• Brain metastases1 recruiting
• Burkitt lymphoma1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Cystic fibrosis1 recruiting
• Depression1 recruiting
• Endometrial cancer1 recruiting
• Hepatitis C1 recruiting
• Huntington's disease1 recruiting
• Hyperparathyroidism1 recruiting
• IgA nephropathy1 recruiting
• Liver cirrhosis1 recruiting
• Long COVID and ME/CFS1 recruiting
• Mild cognitive impairment1 recruiting
• Myocarditis1 recruiting
• Neuroendocrine tumours1 recruiting
• Neurofibromatosis type 11 recruiting
• Obesity1 recruiting
• Psoriasis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Testicular cancer1 recruiting
• Tuberculosis1 recruiting
• Turner syndrome1 recruiting
• Type 1 diabetes1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Withdrawn

  A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

  NCT07084831· Phase 3· European Group for Research In Schizophrenia· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  NCT07630974· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Active, not recruiting

  Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

  NCT07161037· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)

  2025-521681-10-00· Phase 2· Revolution Medicines Inc.· Source

• Active, not recruiting

  Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

  2025-521115-40-00· Phase 2· Bicycletx Limited· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease

  2024-516295-14-00· Phase 2· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Not yet recruiting

  Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

  NCT07118449· Phase 2· XyloCor Therapeutics, Inc.· Source

• Completed

  Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection

  2024-519856-94-00· Phase 2· Biomx Ltd.· Source

• Completed

  Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

  NCT06587451· Phase 3· H e x a l AG· Source

• Active, not recruiting

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· Phase 3· Immutep S.A.S.· Source

• Completed

  A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

  NCT06560645· Phase 1· Prelude Therapeutics Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

  NCT06624228· Phase 3· UCB Biopharma SRL· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Alumis Inc· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Completed

  Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome (REVIVE)

  2024-511628-16-00· Phase 2· Goethe University Frankfurt· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Ipsen Innovation· Source

• Completed

  A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis

  2023-504092-25-00· Phase 2· Enterprise Therapeutics Limited· Source

• Completed

  A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations

  NCT05765734· Phase 1/2· Taiho Oncology Inc.· Source

• Completed

  A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS).

  NCT05975905· Phase 2· Keros Therapeutics Inc.· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

  NCT06335173· Phase 2· Acumen Pharmaceuticals· Source

• Active, not recruiting

  A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

  NCT06018337· Phase 3· DualityBio Inc.· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma

  NCT06018129· Phase 1/2· Genmab A/S· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  The PEERLESS II Study

  NCT06055920· Inari Medical· Source

• Active, not recruiting

  [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

  NCT05870579· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

  NCT06039579· Phase 2· ViiV Healthcare· Source

• Active, not recruiting

  Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE

  2022-502105-15-00· Phase 2· Alumis Inc.· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Celgene· Source

• Completed

  A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

  NCT05665530· Phase 1· Prelude Therapeutics Incorporated· Source

• Completed

  A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV Melanoma in the Adjuvant Setting

  2022-502620-49-00· Phase 1· Amgen Inc.· Source

• Completed

  A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression

  NCT03779230· Phase 1/2· Philogen S.p.A.· Source

• Completed

  A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 12 weeks of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

  NCT04786574· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Active, not recruiting

  Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

  NCT05883644· Phase 3· AstraZeneca· Source

• Completed

  To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

  NCT05911009· Phase 2· Berlin Cures GmbH· Source

• Completed

  A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT05872620· Phase 3· Eli Lilly and Company· Source

• Completed

  An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

  NCT05848258· Phase 2· Eli Lilly and Company· Source

• Completed

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)

  NCT05557942· Phase 3· Aerovate Therapeutics Inc.· Source

• Completed

  A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

  NCT05737940· Phase 2· AstraZeneca· Source

• Completed

  Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

  NCT05804032· Phase 3· University of Heidelberg Medical Center· Source

• Completed

  A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)

  2022-501261-46-00· Phase 2· Kite Pharma Inc.· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Completed

  Vamikibart in Participants With Uveitic Macular Edema

  NCT05642325· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Pfizer· Source

• Completed

  Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)

  NCT05429502· Phase 1/2· Novartis Pharma AG· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus

  NCT05306574· Phase 3· Remegen Co. Ltd.· Source

• Completed

  Phase I study of MGY825 in patients with lung cancer

  NCT05275868· Phase 1· Novartis Pharma AG· Source

• Active, not recruiting

  Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

  NCT05331183· Phase 3· Vertex Pharmaceuticals Incorporated· Source

Showing 50 of 148.

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer95 works · 58 trials
• Parkinson disease68 works · 10 trials
• Hodgkin lymphoma47 works · 15 trials
• Mild cognitive impairment33 works · 7 trials
• Chronic lymphocytic leukaemia27 works · 26 trials
• Glaucoma18 works · 1 trial
• Dystonia18 works · 3 trials
• Aortic stenosis17 works · 4 trials
• Brain metastases17 works · 2 trials
• Macular degeneration17 works · 8 trials
• Neuroblastoma17 works · 6 trials
• Diffuse large B-cell lymphoma16 works · 9 trials
• Systemic sclerosis (scleroderma)13 works · 7 trials
• Aortic aneurysm12 works · 2 trials
• Pulmonary arterial hypertension12 works · 12 trials
• Polycystic kidney disease11 works · 6 trials
• Lewy body dementia10 works · 0 trials
• Nephrotic syndrome8 works · 2 trials
• Essential tremor7 works · 3 trials
• Peripheral artery disease7 works · 1 trial
• Testicular cancer6 works · 1 trial
• Spinal muscular atrophy5 works · 0 trials
• Multiple system atrophy4 works · 0 trials
• Mantle cell lymphoma4 works · 10 trials
• Tourette syndrome3 works · 0 trials